Lecture 7.1 - Gout 2 Flashcards
Allopurinol Hypersensitivity Syndrome Manifestation
Rash, chills, fever, leukopenia, leukocytosis, eosinophilia, and pruritus
Maybe severe and fatal ( hepatotoxicity, vasculitis, SJS and TEN)
AHS prevention
HLA-B*5801 screening
only in high risk, and those who are positive we won’t use allopurinol
AHS management
Discontinue allopurinol at 1st sign of rash
Supportive care
AHS mortality rate
~ 25%
Rare tho
Allopurinol CI
Allopurinol sensitivity
concurrent didanosine use
Allopurinol DI
Didanosine
Azathioprine + 6-mercaptourine (MUST reduce dose of both when used in combo with Allopurinol)
Theophylline
Pegloticase
Loop/thiazide diuretics
Allopurinol monitoring
Efficacy: SUA every few weeks till goal
Safety: HLA-B*5801 test prior to start in high risk pops
High risk pops for HLA-B*5801
Han chinese
Korean
Thai
AA
Allopurinol patient education
Signs and symptoms of allergic reaction
HLA testing
How to use
Febuxostat (Uric) MOA
non-purine inhib of XAI leading to reduced production of uric acid
Febuxostat ADR
Hepatic: abnormal LFTs
GI: nausea
Rheumatologic: Gout flares
Rash, Arthralgia
Febuxostat CI
concomitant use of Azathioprine or 6-mercaptopurine
Febuxostat Precuations
Acute gout flare
CVD events
Hepatoxicity
Serious skin reactions
Febuxostat DI
Azathioprine or 6-mercaptourine
Theophylline
pegloticase
didanosine
Febuxostat Monitoring
Efficacy: SUA after 2 weeks of treatment + periodically
Safety: LFTs at BL and if signs of hepatic injury